肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理

2018-02-20 欧洲肿瘤内科学会 Ann Oncol. 2018 Feb 20.

癌症患者贫血铁缺乏

2018年2月，欧洲肿瘤内科学会(ESMO)发布了癌症患者贫血和铁缺乏的管理指南。贫血和缺铁是实体肿瘤和血液恶性肿瘤，尤其是接受化疗药物治疗患者最常见的并发症，本文主要针对贫血的评估以及补铁治疗方法提出指导建议，主要目的是优化癌症患者贫血和铁缺乏的管理。

中文标题：

2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理

英文标题：

Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.

发布机构：

欧洲肿瘤内科学会

发布日期：

2018-02-20

简要介绍：

2018年2月，欧洲肿瘤内科学会(ESMO)发布了癌症患者贫血和铁缺乏的管理指南。贫血和缺铁是实体肿瘤和血液恶性肿瘤，尤其是接受化疗药物治疗患者最常见的并发症，本文主要针对贫血的评估以及补铁治疗方法提出指导建议，主要目的是优化癌症患者贫血和铁缺乏的管理。

 

拓展指南：与贫血相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理)] GetToolGuiderByIdResponse(projectId=1, id=825601c001559e06, title=2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理, enTitle=Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines., guiderFrom=Ann Oncol. 2018 Feb 20., authorId=null, author=, summary=2018年2月，欧洲肿瘤内科学会(ESMO)发布了癌症患者贫血和铁缺乏的管理指南。贫血和缺铁是实体肿瘤和血液恶性肿瘤，尤其是接受化疗药物治疗患者最常见的并发症，本文主要针对贫血的评估以及补铁治疗方法提出指导建议，主要目的是优化癌症患者贫血和铁缺乏的管理。 , cover=, journalId=null, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会（ESMO，European Society for Medical Oncology )是1975年成立的非盈利组织，是欧洲领先的专业组织，致力于提高肿瘤内科的专业性，推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Tue Feb 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>2018年2月，欧洲肿瘤内科学会(ESMO)发布了癌症患者贫血和铁缺乏的管理指南。贫血和缺铁是实体肿瘤和血液恶性肿瘤，尤其是接受化疗药物治疗患者最常见的并发症，本文主要针对贫血的评估以及补铁治疗方法提出指导建议，主要目的是优化癌症患者贫血和铁缺乏的管理。 </P> <P> </P>拓展指南：<strong>与<font color=red>贫血</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=825601c001559e06" title="2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理" target=_blank>2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=163361c0015a9824" title="重视癌症患者贫血，早期筛查与治疗铁缺乏——欧洲《成年癌症患者铁缺乏的管理意见书》解读" target=_blank>重视癌症患者贫血，早期筛查与治疗铁缺乏——欧洲《成年癌症患者铁缺乏的管理意见书》解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=760a71c00152a5f2" title="NCCN临床实践指南：癌症和化疗诱导的贫血（2018.V2）" target=_blank>NCCN临床实践指南：癌症和化疗诱导的贫血（2018.V2）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=447341c001518e4c" title="再生障碍性贫血诊断与治疗中国专家共识（2017版）解读" target=_blank>再生障碍性贫血诊断与治疗中国专家共识（2017版）解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2fd9a1c001a811b5" title="2017 BCSH指南：药物引起的免疫以及二次免疫溶血性贫血的管理" target=_blank>2017 BCSH指南：药物引起的免疫以及二次免疫溶血性贫血的管理</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E8%B4%AB%E8%A1%80" target=_blank>有关贫血更多指南</a></ul>, tagList=[TagDto(tagId=2813, tagName=癌症患者), TagDto(tagId=420, tagName=贫血), TagDto(tagId=15337, tagName=铁缺乏)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6100, appHits=181, showAppHits=0, pcHits=4181, showPcHits=2262, likes=129, shares=10, comments=4, approvalStatus=1, publishedTime=Mon Feb 26 10:57:36 CST 2018, publishedTimeString=2018-02-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Feb 26 10:57:36 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:51:30 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理)])
2018 ESMO临床实践指南：癌症患者贫血和铁缺乏的管理
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1067936, encodeId=478c106e9360f, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Nov 07 21:52:45 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061998, encodeId=976110619981c, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:48 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051915, encodeId=c506105191501, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 12:07:44 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007027, encodeId=1303100e02780, content=学习一下！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3265570714, createdName=ms5000001117927473, createdTime=Wed Aug 11 20:01:34 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2021-11-07 1e0ba702m86(暂无匿称)

    非常好的文章，受益匪浅。

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1067936, encodeId=478c106e9360f, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Nov 07 21:52:45 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061998, encodeId=976110619981c, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:48 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051915, encodeId=c506105191501, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 12:07:44 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007027, encodeId=1303100e02780, content=学习一下！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3265570714, createdName=ms5000001117927473, createdTime=Wed Aug 11 20:01:34 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2021-10-19 湘雅科教

    非常好的文章，受益匪浅。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1067936, encodeId=478c106e9360f, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Nov 07 21:52:45 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061998, encodeId=976110619981c, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:48 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051915, encodeId=c506105191501, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 12:07:44 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007027, encodeId=1303100e02780, content=学习一下！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3265570714, createdName=ms5000001117927473, createdTime=Wed Aug 11 20:01:34 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2021-09-16 湘雅科教

    受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1067936, encodeId=478c106e9360f, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160717/IMG578BA7C21F5227685.jpg, createdBy=70421925809, createdName=1e0ba702m86(暂无匿称), createdTime=Sun Nov 07 21:52:45 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061998, encodeId=976110619981c, content=非常好的文章，受益匪浅。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Tue Oct 19 17:04:48 CST 2021, time=2021-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051915, encodeId=c506105191501, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Thu Sep 16 12:07:44 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007027, encodeId=1303100e02780, content=学习一下！感谢！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3265570714, createdName=ms5000001117927473, createdTime=Wed Aug 11 20:01:34 CST 2021, time=2021-08-11, status=1, ipAttribution=)]
    2021-08-11 ms5000001117927473

    学习一下！感谢！

    0

相关指南

2018 临床实践指南：青春期后女性癌症患者生育能力保留

国外肿瘤科相关专家小组（统称） · 2018-01-08

重视癌症患者贫血，早期筛查与治疗铁缺乏——欧洲《成年癌症患者铁缺乏的管理意见书》解读

暂未更新 · 2018-01-30

2013 国际临床实践指南：癌症患者中心静脉导管血栓形成的治疗和预防

国际血栓形成和癌症创议(ITAC-CME,International Initiative on Thrombosis and Cancer) · 2013-01-01

2016 CCO临床实践指南：癌症患者抑郁的管理

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2016-07-15